Cambridge Nucleomics awarded Trinity Bradfield Angel Prize 2025

Cambridge Nucleomics Ltd

Cambridge Nucleomics is proud to be awarded the 2025 Trinity Bradfield Angel Prize jointly with BioTryp Therapeutics in recognition of achievements over the past 12 months.

The prize was evaluated and awarded by a distinguished panel of scientific experts, industry leaders and VCs led by Nobel Laureate and serial entrepreneur Sir Greg Winter. This recognition further validates our commercial trajectory and the disruptive potential of our single-molecule diagnostic platform in acute clinical care. 

Judging panel including Nobel Laureate Sir Greg Winter and Kerry Baldwin of IQ Capital
The judging panel included Nobel laureate Sir Greg Winter and Kerry Baldwin of IQ Capital.

After an extremely hectic and successful year 2024, we celebrate this recognition of our hard work as we gather critical momentum towards closing our pre-seed round in the coming weeks. We have a small SEIS allocation remaining, if interested reach out!